SNOA - Sonoma Pharma +35% on Crown Laboratories partnership

Sonoma Pharmaceuticals (SNOA) +35.3% post-market after announcing a partnership with Crown Laboratories for a license and supply agreement for exclusive rights to sell and market products for the over-the-counter dermatological market in the U.S.Under the deal terms, Crown will sell Sonoma's Microcyn technology dermal sprays and gels targeting itch and pain under the Sarna brand.Sonoma will continue to sell its prescription strength products, while Crown will distribute an OTC version available without prescription.Insider buying and growing sales make Sonoma a buy, Jonathan Faison writes in a bullish analysis published recently on Seeking Alpha.

For further details see:

Sonoma Pharma +35% on Crown Laboratories partnership